News & Updates
Filter by Specialty:
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
byAudrey Abella
The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
Dietary intake of n-3 PUFA prevents all-cause, CV deaths in diabetic people
02 Nov 2024
Individuals with prediabetes or diabetes may benefit from increased dietary intake of n-3 polyunsaturated fatty acids (PUFAs), particularly alpha-linolenic acid (ALA) and docosapentaenoic acid (DPA), which help lower the risk of all-cause and cardiovascular mortality, suggests a US study.
